Sildenafil Potentiates the Therapeutic Efficacy of Docetaxel in Advanced Prostate Cancer by Stimulating NO-cGMP Signaling
Open Access
- 26 August 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 26 (21) , 5720-5734
Abstract
Purpose: Docetaxel plays an indispensable role in the management of advanced prostate cancer. However, more than half of patients do not respond to docetaxel, and those good responders frequently experience significant cumulative toxicity, which limits its dose duration and intensity. Hence, a second agent that could increase the initial efficacy of docetaxel and maintain tolerability at biologically effective doses may improve outcomes for patients. Experimental Design: We determined phosphodiesterase 5 (PDE5) expression levels in human and genetically engineered mouse (GEM) prostate tissues and tumor-derived cell lines. Furthermore, we investigated the therapeutic benefits and underlying mechanism of PDE5 inhibitor sildenafil in combination with docetaxel using in vitro, Pten conditional knockout (cKO), derived tumoroid and xenograft prostate cancer models. Results: PDE5 expression was higher in both human and mouse prostate tumors and cancer cell lines compared with normal tissues/cells. In GEM prostate-derived cell lines, PDE5 expression increased from normal prostate (wild-type) epithelial cells to androgen-dependent and castrated prostate-derived cell lines. The addition of physiologically achievable concentrations of sildenafil enhanced docetaxel-induced prostate cancer cell growth inhibition and apoptosis in vitro, reduced murine 3D tumoroid growth, and in vivo tumorigenicity as compared with docetaxel alone. Furthermore, sildenafil enhanced docetaxel-induced NO and cGMP levels thereby augmenting antitumor activity. Conclusions: Our results demonstrate that sildenafil's addition could sensitize docetaxel chemotherapy in prostate cancer cells at much lesser concentration than needed for inducing cell death. Thus, the combinatorial treatment of sildenafil and docetaxel may improve anticancer efficacy and reduce chemotherapy-induced side-effects among patients with advanced prostate cancer.Keywords
Funding Information
- NIH (U01 CA185148)
- NIH (R01 CA221813, DK120866, HL118808)
- NIH (R01 HL134366)
- Department of Defense (W81XWH-18-1-0308, PC170891)
This publication has 53 references indexed in Scilit:
- Sulindac Selectively Inhibits Colon Tumor Cell Growth by Activating the cGMP/PKG Pathway to Suppress Wnt/β-Catenin SignalingMolecular Cancer Therapeutics, 2013
- Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunctionProceedings of the National Academy of Sciences, 2010
- Mitochondria and cell death: outer membrane permeabilization and beyondNature Reviews Molecular Cell Biology, 2010
- Mouse Prostate Cancer Cell Lines Established from Primary and Postcastration Recurrent TumorsDiscover Oncology, 2010
- Signal integration by JNK and p38 MAPK pathways in cancer developmentNature Reviews Cancer, 2009
- PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor modelBrain Research, 2008
- Tumor Immunobiological Differences in Prostate Cancer between African-American and European-American MenCancer Research, 2008
- Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cellsJournal of Cellular Biochemistry, 2004
- Tissue expression, distribution, and regulation of PDE5International Journal Of Impotence Research, 2004
- Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cellsBlood, 2003